CoChat

An update on the pharmacotherapy of neovascular age-related macular degeneration

Freund, K Bailey, Mrejen, Sarah, Gallego-Pinazo, Roberto · 2013 · Expert Opinion on Pharmacotherapy
Cited by 44

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Neovascular age-related macular degeneration (AMD) is currently the most common cause of legal blindness in industrialized countries. The advent of pharmacotherapy with intravitreal VEGF inhibitors has greatly improved outcomes for the treatment of this disease. AREAS COVERED: The present review is divided into two major sections: the period prior to the use of anti-VEGF agents (triamcinolone acetonide, verteporfin photodynamic therapy) and the period following their introduction (pegaptanib sodium, bevacizumab, ranibizumab, aflibercept). The main pharmacological and clinical characteristics of each therapy are summarized. EXPERT OPINION: Monotherapy with anti-VEGF agents is currently the 'gold standard' for treating neovascular AMD, but, with several drug choices and various different dosing regimens available, there is still wide variability in how individual clinicians manage their patients. Despite improved visual outcomes, there remains a significant unmet need for better treatments as the frequent office visits and injections associated with anti-VEGF therapy are costly and place a significant burden on patients, their family members and physicians.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/14656566.2013.787410

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 44

Metadata

Authors
Freund, K. B., Mrejen, S., & Gallego-Pinazo, R.
Venue
Expert Opinion on Pharmacotherapy
Published
2013-04-08
Volume
14
Issue
8
Pages
1017-1028
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W2105661731
Cited by
44
References
19
FWCI
5.42
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An update on the pharmacotherapy of neovascular age-related macular degeneration. https://app.cochat.ai/papers/10.1517/14656566.2013.787410
The paper
Freund, K. B., Mrejen, S., & Gallego-Pinazo, R. (2013). An update on the pharmacotherapy of neovascular age-related macular degeneration. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2013.787410

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.